Abstract:Background: Double filtration plasmapheresis (DFPP) and (IA) are both used to clear antibody. However, the clinical efficacy and safety of DFPP in patients with anti-glomerular basement membrane (anti-GBM) disease are unclear. Methods: The 28 enrolled patients diagnosed serologically and pathologically with anti-GBM disease from 2003 to 2013 included 16 treated with DFPP and 12 with IA, with all patients administered immunosuppressive agents. DFPP consisted of an EC50W filter for plasma separation and an EC20W filter for plasma fractionation. A double volume of plasma was processed, and each patient received a 30-40 g human albumin supplement during each session. IA consisted of 10 cycles per session, with 8-10 sessions performed daily or every other day and each session regenerating 30-60 L of plasma. Serum anti-GBM antibodies and IgG were measured, and urinary and blood tests were performed, before and after each procedure. Renal function and outcome were determined. Results: The 28 patients consisted of 13 males and 15 females, of median age 44.5 years (range, 22.5-57 years). Six patients had pulmonary hemorrhage and 18 had serum creatinine concentrations >500 umol/L. The average serum creatinine concentration at early onset of disease was 525 umol/L while the peak concentration was 813 umol/L. All patients showed progressive increases in serum creatinine and required CRRT during the course of disease. Pathological examination showed an average 73.9% of crescents (range, 54.6-95.4%).The clinical and pathological features of the DPPP and IA groups were similar. Efficacy of clearing anti-GBM antibody was similar in the two groups (59.0 vs. 71.2%, P = 1.00), although fewer patients in the DFPP group experienced reduced IgG (62.7 vs. 83.5%, p = 0.002). One patient each had a pulmonary hemorrhage and a subcutaneous hemorrhage during treatment, but there were no other serious complications. At the end of follow-up, patient survival and renal survival were similar in the DFPP and IA groups. Conclusion: DPPP plus immunosuppressive therapy efficiently and safely removed anti-GBM antibodies. The fewer plasma-associated side effects and reduced loss of IgG suggest that DFPP may be a better treatment choice for anti-GBM disease, especially in patients with insufficient plasma.

Staphylococcal Protein A Immunoadsorption for Anti-Glomerular Basement Membrane Diseases--report of Five Cases

Protein A immunoadsorption for anti-glomerular basement membrane nephritis

Staphylococcal protein A immunoadsorption for Goodpasture's syndrome in four Chinese patients

PROTEIN A IMMUNOADSOPTION FOR THE THERAPY OF RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS-5 CASE REPORT

Progress in Pathogenesis of Immunoglobin A Nephropathy

Five years' experience at one centre with protein A immunoadsorption in patients with deleterious allo/autoantibodies (anti-HLA antibodies, autoimmune bleeding disorders) and post-transplant patients relapsing with focal glomerular sclerosis.

Comparison of double filtration plasmapheresis with immunoadsorption therapy in patients with anti-glomerular basement membrane nephritis

Successful Treatment of Patients with Lipoprotein Glomerulopathy by Protein A Immunoadsorption: a Pilot Study.

Therapeutic Effect of Immunoadsorption in Severe Lupus Nephritis with Vascular Lesions

High-frequency plasma exchange therapy for immunocompromised, type I crescentic glomerulonephritis complicated with IgA nephropathy: A case report and literature review

Anti-glomerular Basement Membrane-Antibody Mediated Disease with Normal Renal Function——3 Cases Report

The clinical study of staphylococcal protein A immunoadsorption in the treatment of generalized myasthenia gravis

Prognosis of Anti-Glomerular Basement Membrane Antibody Associated Diseases:Predictive Value of Clinical,histological and Serological Data

Effect of Immunoadsorption Therapy in Patients with Lipoprotein Glomerulopathy

Plasmapheresis, immunosuppressive therapy and anti-GBM disease prognosis: a cohort study of 107 patients

Rituximab for the treatment of refractory anti-glomerular basement membrane disease

The Prevalence and Characteristics of Circulating IgA Anti-Glomerular Basement Membrane Autoantibodies in Anti-Glomerular Basement Membrane Disease

Clinical and Immunological Characteristics of Patients with Combined Anti-Glomerular Basement Membrane Disease and IgA Nephropathy.

Clinicopathological features and outcome of antibody-negative anti-glomerular basement membrane disease.

Anti-Glomerular Basement Membrane Disease Outcomes Of Different Therapeutic Regimens In A Large Single-Center Chinese Cohort Study

Effects of Protein A Immunoadsorption Therapy in Patients with ANCA-associated Vasculitis and Renal Involvement